Health Partners •••• Medicare

PRIOR AUTHORIZATION REQUEST FORM

Mavenclad - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

atient Name:	Prescriber Name:
ember Number:	Fax: Phone:
ate of Birth:	Office Contact:
ne of Business: Medicare	NPI: State Lic ID:
ddress:	Address:
ity, State ZIP:	City, State ZIP:
imary Phone:	Specialty/facility name (if applicable):
REQUEST FOR EXPEDITED REVIEW: By checking this boe life or health of the enrollee or the enrollee's ability to r	ox and signing below, I certify that applying the 72 hour standard review timeframe may seriously jeopardize regain maximum function.
Orug Name:	
Strength:	
Directions / SIG:	
Please attach any pertinent medical hist	tory including labs and information for this member that may support approval.
Pleas	se answer the following questions and sign.
Q1. Is the patient 18 years of age or olde	r?
☐ Yes	□ No
Q2. Does the patient have a confirmed di progressive disease?	iagnosis of multiple sclerosis including relapsing-remitting or active secondary
Yes	□ No
Q3. Is the requested drug being prescribe	ed by or in consultation with a neurologist?
Yes	☐ No
O4. Does the nationt have any contraind	ications to the requested drug? Contraindications include but not limited to:
Current malignancy, pregnancy, active in	fection (HIV, hepatitis, TB), hypersensitivity to cladribine, clinically isolated the FDA-approved prescribing information, female patients intending to days after the last dose.
Current malignancy, pregnancy, active in syndrome, any contraindications listed in	the FDA-approved prescribing information, female patients intending to
Current malignancy, pregnancy, active in syndrome, any contraindications listed in breastfeed on a treatment day and for 10	the FDA-approved prescribing information, female patients intending to days after the last dose.
Current malignancy, pregnancy, active in syndrome, any contraindications listed in breastfeed on a treatment day and for 10 Yes	the FDA-approved prescribing information, female patients intending to days after the last dose.
Current malignancy, pregnancy, active in syndrome, any contraindications listed in breastfeed on a treatment day and for 10 Yes Q5. Is the patient of reproductive potential Yes	the FDA-approved prescribing information, female patients intending to days after the last dose. No

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



PRIOR AUTHORIZATION REQUEST FORM

Mavenclad - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug. labs) left blank, illegible, or not attached WILL delay the review process.

itient Name:	Prescriber Name:	
☐ Yes	□ No	
Q8. Has documentation of the patient ha	aving trial and failure or intolerance to at least one alternative drug inclu	ded?
Yes	□ No	
Q9. Additional Information:		
Q10. Duration:		
12 months		
Prescriber Signature	Date	
	2022 Medicare Prior Authorizati	ion Regu